What are us european and national guidelines from resource limited settings rls recommending
Download
1 / 12

What are US, European and National Guidelines from Resource Limited Settings (RLS) Recommending ? - PowerPoint PPT Presentation


  • 80 Views
  • Uploaded on

What are US, European and National Guidelines from Resource Limited Settings (RLS) Recommending ?. G. Gavriilidis, PJ. Easterbrook, L. Muhe, M. Vitoria World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011. Current Recommendations. Areas of consensus and discrepancy.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' What are US, European and National Guidelines from Resource Limited Settings (RLS) Recommending ?' - yasuo


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
What are us european and national guidelines from resource limited settings rls recommending

What are US, European and National Guidelines from Resource Limited Settings (RLS) Recommending?

G. Gavriilidis, PJ. Easterbrook, L. Muhe, M. Vitoria

World Health Organization, HIV Department (ATC)

Geneva, Switzerland

July 2011


Current recommendations
Current Recommendations Limited Settings (RLS) Recommending


Areas of consensus and discrepancy
Areas of consensus and discrepancy Limited Settings (RLS) Recommending

Consensus:

  • Amphotericin B + 5FC as first line in high income countries and AmB + Fluconazole in RLS (IDSA and MSF)

  • Lack of specific monitoring and toxicity management guidance

    Discrepancy:

  • Dose of Amphotericin B (0.5-1, 0.7-1,1 mg/kg)

  • Fluconazole induction dose (400mg, 400-800mg, 800mg, 800-1200 mg, 1.2-2g) and consolidation dose (400mg, 800mg), and duration.

  • Criteria for discontinuation of secondary prophylaxis (Lifelong, Immune reconstitution on ART, CD4cell count and HIV RNA criteria)

  • Role of Itraconazole (alternative induction, consolidation or maintenance)


Survey of national oi guidelines in rls n 33
Survey of National OI Guidelines in RLS Limited Settings (RLS) Recommending(n=33)

  • Sources:

  • In-house databases

  • Key websites

  • WHO regional and country

    offices

  • Other key informants


1 st line induction n 33

Africa Limited Settings (RLS) Recommending: Botswana, Côte d'Ivoire, Kenya, Madagascar, Namibia, Rwanda, Senegal, Zambia,

Americas: Argentina, Dom Republic, Ecuador, Guatemala, Panama, Paraguay, Venezuela,

Asia: Bhutan

(16)

(12)

Africa: Comoros, Ethiopia, Lesotho, Liberia, Tanzania

Americas: Guyana

Asia: China, India, Lao PDR, Malaysia, Myanmar, Vietnam

(2)

Cuba, El Salvador

(2)

Mozambique, Haiti

Nigeria

(1)

1st Line Induction (n=33)

  • Recommended AmB dose varied (0.4, 0.6-1, 0.7, 0.7-1, 1 mg/kg/day)

  • Two countries recommended either lower than the standard dose of AmB (Mozambique and Malaysia, 0.4mg/kg) or not per kg based dosing (China, 30-40mg QD)


All alternative regimens n 33
All Alternative Regimens (n=33) Limited Settings (RLS) Recommending

Number of

Alternatives Provided

0: n=7

1: n=18

2: n=6

5: n=1

IV duration: 3d-10w (median=2w)

(1)

(3)

(8)

(4)

PO duration: 2-12w (median=8w)

(4)

(15)

(1)


Minimum induction fluconazole dose n 15
Minimum Induction Fluconazole dose (n=15) Limited Settings (RLS) Recommending

Mozambique, Cuba, Ecuador

(3)

Africa: Botswana, Côte d'Ivoire, Ethiopia, Kenya, Lesotho, Senegal, Tanzania

Americas: Argentina, El Salvador, Haiti

Duration: 3d (n=1); 4w (n=1); 6w (n=1)

(10)

Duration: 2w (n=2); 4-6w (n=2); 8-10w (n=3); 12w (n=2); lifelong (n=1)

Guatemala, Paraguay

(2)

Duration: 8-10w (n=1); lifelong (n=1)


Consolidation fluconazole dose n 26
Consolidation Fluconazole dose (n=26) Limited Settings (RLS) Recommending

200mg

(1)

Senegal

Africa: Botswana, Comoros, Ethiopia,, Kenya, Lesotho, Liberia, Madagascar, Mozambique, Namibia, Rwanda, Tanzania

Americas: Argentina, Ecuador Guatemala, Guyana, Paraguay, Venezuela

Asia: Bhutan, India, Myanmar, Vietnam

400mg

(1)

Cuba

(22)

(2)

Côte d'Ivoire, Malaysia


Treatment monitoring recommendations n 33
Treatment Monitoring Recommendations (n=33) Limited Settings (RLS) Recommending

Africa: Madagascar, Namibia, Nigeria, Rwanda, Senegal

Americas: Panama, Paraguay, Venezuela

(8)

(23)

(2)

Botswana, Kenya

Complete: Guidelines that cover neurological, renal, liver, blood and electrolyte monitoring and frequency for CM

Partial/Unspecific: Guidelines that omit one or more of the above, or give general instructions for patient follow-up (not specific to CM treatment)


Focus of monitoring n 33
Focus of Monitoring (n=33) Limited Settings (RLS) Recommending

(6)

(11)

(12)

(7)

(10)

(7)


Secondary prophylaxis n 29
Secondary prophylaxis (n=29) Limited Settings (RLS) Recommending

Duration

  • 77%: did not specify

  • 15%: indefinite

  • 8%: until CD4 >100-200 cells/mm3 on ART

(29)

200mg (n=29)

Africa: Côte d'Ivoire, Rwanda

Americas: Dom. Republic, Panama, Paraguay, Venezuela

Asia: China

(7)

0.5mg QW (n=2); 0.6mg QW (n=2) 1mg QW (n=3)

Argentina, Panama, Ecuador, Venezuela

(4)

200mg (n=2); 400mg (n=2)


Conclusions
Conclusions Limited Settings (RLS) Recommending

  • Still wide variation in drug, dose and duration of initial and alternative treatment regimens

  • Specific areas of concern e.g.:

    • Too low a dose (or too short a duration) of oral fluconazole regimens for induction and consolidation

    • Use of amphotericin B as maintenance

  • Few national guidelines include explicit, complete and detailed instructions for monitoring and management of toxicities

  • Minimal paediatric guidance


ad